BPMC logo

Blueprint Medicines Corporation

BPMC

BPMC: Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

more

Show BPMC Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of BPMC by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BPMC's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Egfr inhibitors Aug. 08, 2023
  • Patent Title: Inhibitors of activin receptor-like kinase Apr. 25, 2023
  • Patent Title: Map4k1 inhibitors Dec. 27, 2022
  • Patent Title: Inhibitors of ret Mar. 22, 2022
  • Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Mar. 15, 2022
  • Patent Title: Prkc fusions Mar. 01, 2022
  • Patent Title: Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase Feb. 01, 2022
  • Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 13, 2021
  • Patent Title: Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to kit and pdgfr Jun. 22, 2021
  • Patent Title: Pik3c2g fusions Dec. 29, 2020
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Dec. 29, 2020
  • Patent Title: Compositions and methods for treating kit- and pdgfra-mediated diseases Nov. 10, 2020
  • Patent Title: Compositions useful for treating disorders related to kit Oct. 20, 2020
  • Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Sep. 15, 2020
  • Patent Title: Pik3ca fusions Jun. 02, 2020
  • Patent Title: Inhibitors of activin receptor-like kinase Jun. 02, 2020
  • Patent Title: Inhibitors of ret Mar. 10, 2020
  • Patent Title: Ntrk2 fusions Sep. 10, 2019
  • Patent Title: Raf1 fusions Aug. 13, 2019
  • Patent Title: Fgr fusions Aug. 06, 2019
  • Patent Title: Prkc fusions Aug. 06, 2019
  • Patent Title: Tert fusions Aug. 06, 2019
  • Patent Title: Compounds and compositions useful for treating disorders related to ntrk Aug. 06, 2019
  • Patent Title: Method for detection of a tecr:pkn1 or an anxa4:pkn1 gene fusion Apr. 02, 2019
  • Patent Title: Inhibitors of activin receptor-like kinase Mar. 19, 2019
  • Patent Title: Compounds useful for treating disorders related to ret Mar. 12, 2019
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Mar. 05, 2019
  • Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Feb. 12, 2019
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Feb. 05, 2019
  • Patent Title: Inhibitors of ret Jan. 22, 2019
  • Patent Title: Compounds useful for treating disorders related to ret Jul. 31, 2018
  • Patent Title: Inhibitors of ret Jul. 24, 2018
  • Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 10, 2018
  • Patent Title: Compositions useful for treating disorders related to kit and pdgfr Jun. 19, 2018
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Jun. 19, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Apr. 17, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Feb. 06, 2018
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Jul. 04, 2017
  • Patent Title: Compositions useful for treating disorders related to kit Jun. 27, 2017
  • Patent Title: Compositions useful for treating disorders related to kit Nov. 22, 2016
  • Patent Title: Inhibitors of the fibroblast growth factor receptor May. 17, 2016
  • Patent Title: Compositions useful for treating disorders related to kit May. 10, 2016
  • Patent Title: Compositions useful for treating disorders related to kit Dec. 01, 2015
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Sep. 08, 2015
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Aug. 12, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of BPMC in WallStreetBets Daily Discussion

BPMC News

Recent insights relating to BPMC

CNBC Recommendations

Recent picks made for BPMC stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BPMC

Corporate Flights

Flights by private jets registered to BPMC